French multinational pharmaceutical company developing vaccines, treatments for diabetes, cardiovascular diseases, oncology, and rare diseases.
Profile & Fundamentals
Sanofi: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Sanofi Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Company profile record
Sanofi SA
Common Stock · Health Care · Pharmaceuticals
Company
- Company / asset
- Sanofi SA
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Pharmaceuticals
- HQ
- 🇫🇷 France
- Head office
- 46, avenue de la Grande ArmEe, Paris, France, 75017
Leadership & scale
- Chief executive
- Ms. Belen Garijo Lopez M.D.
- CEO year born
- 1960
- Full-time employees
- 74.8K
- Fiscal year end
- December
Fundamentals snapshot
- Market Cap
- EUR 84.5B
- P/E
- 12.5x
- Revenue (Q2 26)
- EUR 12.3B
- Profit (Q2 26)
- EUR 343.0M
- Dividend Yield
- 4.4%
- Revenue (FY 25)
- EUR 46.7B
- Shares in public float
- 1.1B
- Insider ownership
- 10.31%
Reporting & identifiers
- Symbol
- SAN.PAR
- Listing
- 🇫🇷 France | Dividend Tax: 25%
- Ticker Currency
- EUR
- Income Statement Currency
- EUR
- Balance Sheet Currency
- EUR
- Cash Flow Currency
- EUR
- EPS Currency
- EUR
- Contract Type
- SPOT
- ISIN
- FR0000120578
- Asset ID
- equity_56b28eb6-34ca-56e9-a0de-0798b00e74da
Ownership
Shares Outstanding
Latest: 1.2B | Max: 1.3B | Min: 1.2B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
90.27%
1.1B latest reported shares
Insider Ownership
10.31%
Latest reported insider stake
Short Float
--
Latest reported short interest / float
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 1,252,900,000 |
| 2018-01-01 | 1,245,600,000 |
| 2019-01-01 | 1,253,100,000 |
| 2020-01-01 | 1,255,100,000 |
| 2021-01-01 | 1,254,900,200 |
| 2022-01-01 | 1,257,884,200 |
| 2023-01-01 | 1,253,600,000 |
| 2024-01-01 | 1,253,600,000 |
| 2025-01-01 | 1,212,700,000 |
| 2026-01-01 | 1,196,600,000 |
Top Holders
Available reported ownership records.
No reported records are available in this preview.
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Headline financial reports show sharp profit swings that conceal an underlying commercial acceleration. In fiscal 2025, revenue reached 46.7 billion euros with net income expanding to 7.81 billion euros. While second-quarter 2026 reported accounting profit dropped sharply to 343 million euros, this decline was driven by a one-off 1.03-billion-euro pipeline impairment following the termination of uncompetitive eczema studies, rather than falling medicine demand. Underneath these accounting charges, core business performance is strengthening. Driven by blockbuster immunology demand and rapid uptake of infant respiratory and hemophilia therapies, quarterly operating sales grew by double digits. Management consequently upgraded full-year 2026 constant-currency sales targets to approximately 10%.
Headline financial reports show sharp profit swings that conceal an underlying commercial acceleration. In fiscal 2025, revenue reached 46.7 billion euros with net income expanding to 7.81 billion euros. While second-quarter 2026 reported accounting profit dropped sharply to 343 million euros, this decline was driven by a one-off 1.03-billion-euro pipeline impairment following the termination of uncompetitive eczema studies, rather than falling medicine demand. Underneath these accounting charges, core business performance is strengthening. Driven by blockbuster immunology demand and rapid uptake of infant respiratory and hemophilia therapies, quarterly operating sales grew by double digits. Management consequently upgraded full-year 2026 constant-currency sales targets to approximately 10%.
Revenue, Net Income, and Free Cash Flow
Latest: EUR 46.7B | Max: EUR 46.7B | Min: EUR 2.8B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 9x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Underlying profit margins reflect powerful commercial pricing power driven by high-value specialty biologics. Gross margins expanded to 72.1% in 2025, demonstrating that complex medicines command premium prices across global healthcare systems. While reported operating margins temporarily dipped to 20.5% due to clinical write-downs and restructuring costs, core business profitability remained strong. Selling off lower-margin consumer lines structurally lifts future profit margins toward 28% to 30%. As blockbuster respiratory indications scale and the launch portfolio expands without requiring proportional overhead, operating leverage will naturally widen profit margins, generating massive cash flows to reinvest in the business and reward shareholders.
Underlying profit margins reflect powerful commercial pricing power driven by high-value specialty biologics. Gross margins expanded to 72.1% in 2025, demonstrating that complex medicines command premium prices across global healthcare systems. While reported operating margins temporarily dipped to 20.5% due to clinical write-downs and restructuring costs, core business profitability remained strong. Selling off lower-margin consumer lines structurally lifts future profit margins toward 28% to 30%. As blockbuster respiratory indications scale and the launch portfolio expands without requiring proportional overhead, operating leverage will naturally widen profit margins, generating massive cash flows to reinvest in the business and reward shareholders.
Profitability Margins
Latest: 72.1% | Max: 72.1% | Min: 7.3%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
72.1%
Gross profit / revenue
Operating Margin
20.5%
Operating income / revenue
Net Margin
16.7%
Net income / revenue
FCF Margin
19.2%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 36,777,760,000 | 4,991,540,000 | 6,100,300,000 |
| 2017-12-31 | 43,102,990,000 | 10,015,040,000 | 6,453,370,000 |
| 2018-12-31 | 40,671,780,000 | 4,908,840,000 | 4,069,800,000 |
| 2019-12-31 | 42,146,720,000 | 3,084,480,000 | 6,639,360,000 |
| 2020-12-31 | 45,590,180,000 | 14,998,680,000 | 6,508,700,000 |
| 2021-12-31 | 44,659,500,000 | 7,094,220,000 | 9,666,060,000 |
| 2022-12-31 | 43,125,280,000 | 8,956,970,000 | 8,907,750,000 |
| 2023-12-31 | 45,219,900,000 | 5,940,000,000 | 9,502,900,000 |
| 2024-12-31 | 46,057,440,000 | 5,782,400,000 | 6,121,440,000 |
| 2025-12-31 | 54,657,720,000 | 9,141,210,000 | 10,515,960,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 9.45 | Trailing four quarters |
| 2024-12-31 | 20.46 | Trailing four quarters |
| 2023-12-31 | 20.84 | Trailing four quarters |
| 2022-12-31 | 13.5 | Annual net income |
| 2021-12-31 | 17.77 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 69.16 | 18.82 | 13.57 | 16.59 |
| 2017-12-31 | 68.4 | 16.02 | 23.24 | 14.97 |
| 2018-12-31 | 68.27 | 13.11 | 12.07 | 10.01 |
| 2019-12-31 | 68.18 | 8.11 | 7.32 | 15.75 |
| 2020-12-31 | 67.6 | 37.77 | 32.9 | 14.28 |
| 2021-12-31 | 68.73 | 20.74 | 15.89 | 21.64 |
| 2022-12-31 | 70.55 | 32.62 | 20.77 | 20.66 |
| 2023-12-31 | 69.3 | 31.57 | 13.14 | 21.01 |
| 2024-12-31 | 70.21 | 32.63 | 12.55 | 13.29 |
| 2025-12-31 | 72.07 | 20.54 | 16.72 | 19.24 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-22.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.